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DNA methylation is an important epigenetic mechanism
that ensures correct gene expression and maintains genetic
stability. DNA methyltransferase 1 (DNMT1) is the
primary enzyme that maintains DNA methylation during
replication. Dysregulation of DNMT1 is implicated in a
variety of diseases. DNMT1 protein stability is regulated
via various post-translational modifications, such as acetyl-
ation and ubiquitination, but also through protein–protein
interactions. These mechanisms ensure DNMT1 is properly
activated during the correct time of the cell cycle and at
correct genomic loci, as well as in response to appropriate
extracellular cues. Further understanding of these regula-
tory mechanisms may help to design novel therapeutic
approaches for human diseases.
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Introduction
Epigenetic changes—inheritance of genetic traits that cannot
be explained by changes in the DNA sequence—rely heavily
on DNA methylation to propagate responses to environmental
and/or developmental cues [1]. Enzymes that catalyze this
modification are part of the DNA methyltransferase family.
Among them, DNA (cytosine-5-)-methyltransferase 3 alpha
and DNA (cytosine-5-)-methyltransferase 3 beta are thought to
be de novo DNA methyltransferases, which methylate genes
to regulate them in a developmental context. Conversely,
DNA (cytosine-5-)-methyltransferase 1 (DNMT1) specifically
methylates DNA during replication to maintain correct methy-
lation patterns on the new DNA strand [2].
DNA methylation via DNMT1 ensures correct formation of
heterochromatin [3,4] and promoter repression via histones [5].
Interactions between histone deacetylases and DNMT1 further
underscore the relationship between chromatin and DNMT1
[6], but also belie a mechanism for DNMT1 regulation [7].
Correct regulation of DNMT1 and its relationship with
histone modifications becomes especially important in the
case of ‘bivalent chromatin’—those promoters with both ac-
tivating and repressive histone marks. The latter modifica-
tions could inadvertently recruit DNMT1 to aberrantly
methylate promoters, permanently turning off a gene that
should otherwise be temporarily silenced [8].
Dysregulation of DNMT1 activity causes human diseases,
such as cancer [9] and various genetic disorders [10,11].
DNMT1 mutations are found in patients with hereditary
sensory neuropathy [12,13] and in human cancers [14].
Cancer epigenetic landscapes are generally defined by global
DNA hypomethylation with localized promoter hypermethy-
lation at tumor suppressors [8]. These tumor suppressors
include Cadherin 1, Type 1, E-Cadherin [15], adenomatous
polyposis coli [16], Ras association domain family member 1
[17], p16 and TIMP metallopeptidase inhibitor 3 [18] among
many others. As a corollary, both overexpression and develop-
mental disruption of DNMT1 will lead to tumorigenesis in
both experimental models and human cancer studies [19–24].
As such, given the complications of bivalent chromatin and
the ramifications of incorrect DNMT1 protein levels, regula-
tion of DNMT1 becomes especially vital and occurs through
a variety of pathways [9,25] (summarized in Table 1).
Although DNMT1 is also regulated at the transcriptional level
[34–37], this review will focus on emerging mechanisms of
post-translational regulation of DNMT1 protein stability.
Regulation of DNMT1 Protein Stability by
Acetylation and Ubiquitination
DNMT1 protein abundance is tightly regulated during the cell
cycle: it peaks at the early S phase, decreases after the S phase,
and reaches lowest level at the G1 phase [26]. The primary
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function of DNMT1 is to methylate newly synthesized DNA
during the S phase [1]. A crucial component of the replication
machinery, proliferating cell nuclear antigen (PCNA), interacts
with DNMT1 to ensure its correct positioning at the replication
fork and at the appropriate time during replication [38,39]. The
chromatin-associated ubiquitinase ubiquitin-like with PHD
and ring finger domains 1 (UHRF1) [40,41] binds to hemi-
methylated loci that are formed during DNA replication,
helping DNMT1 co-localize with the replication fork [42] as
well as chromatin [43].A recent study using an Xenopus inter-
phase egg extract system suggests an alternative mechanism
that DNMT1 is recruited to the replication forks through
binding to ubiquitinated histone H3, whereas the ubiquitina-
tion of histone is catalyzed by UHRF1 [44].
In addition to localizing DNMT1 correctly, UHRF1 also
causes its degradation, as it ubiquitinates acetylated DNMT1.
The acetyltransferase Tip60 protein levels are elevated in the
late S phase, which, in turn, leads to DNMT1 acetylation.
Acetylation of DNMT1 enhances its binding affinity with
UHRF1 and thus triggers DNMT1 ubiquitination and degrad-
ation (Fig. 1) [26]. Conversely, DNMT1 is deacetylated by
histone deacetylase 1 (HDAC1) and deubiquitnated by ubi-
quitin specific peptidase 7 (HAUSP), thereby stabilizing
DNMT1 (Fig. 1) [26,29,30]. This model bears out in vivo, as
DNMT1 levels correlate with HAUSP levels in human
tumors [26]. Furthermore, the role of Tip60 and UHRF1 in
DNMT1 stability connects with the DNA damage response
via ataxia telangiectasia mutated (ATM). When phosphory-
lated ATM interacts with DNMT1, it coordinates its acetyl-
ation and subsequent ubiquitination via Tip60 and UHRF1
[45], consistent with previous reports [26]; accordingly, Rb
antagonizes ATM and helps stabilize DNMT1 [45]. Tip60
acetylation can be regulated via extracellular cues, as the auto-
crine/paracrine signaling molecule gastrokine 1 decreases
DNMT1 levels via upregulation of Tip60 and concomitant
DNMT1 acetylation [27]. Other enzymes that modulate
DNMT1 acetylation include K (lysine) acetyltransferase 2B
for acetylation or sirtuin 1 for deacetylation [28]. Sirt1 deace-
tylation is especially notable for modulating DNMT1’s
methyltransferase activity as well [28].
Regulation of DNMT1 Protein Stability by
Phosphorylation and Methylation
DNMT1 stability is also affected by lysine methylation.
Specifically, DNMT1 binds with the histone methyltransfer-
ase Set7 and becomes methylated, especially during the
S/G2 phase of the cell cycle. This mark catalyzes DNMT1
ubiquitination and subsequent degradation [31]. Conversely,
the histone demethylase lysine (K)-specific demethylase 1A
(LSD1) interacts with and demethylates DNMT1; when
LSD1 is knocked out, cells experience global DNA hypo-
methylation and decreased DNMT1 levels (Fig. 1) [32].
Table 1. List of modifications to DNMT1, the enzymes that catalyze them, and the resultant effects on DNMT1 stability
Modification Enzyme Effect on DNMT1 References
Acetylation Tip60, p300, PCAF Destabilizing [26–28]
Deacetylation HDAC1, Sirt1 Stabilizing [26,28–30]
Methylation Set7 Destabilizing [31]
Demethylation LSD1 Stabilizing [32]
Phosphorylation Akt1 Stabilizing [33]
Figure 1. Post-translational modifications regulate DNMT1 protein stability (A) Destabilizing modifications. Methylation catalyzed by Set7 and
Tip60 acetylation activity result in UHRF1 ubiquitination of DNMT1. (B) Stabilizing modifications. Demethylation by Lsd1 and/or Akt1 phosphorylation
counteracts Set7 methylation. Deacetylation via HDAC1 stabilizes DNMT1, and HAUSP/USP7 deubiquitinates DNMT1.
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Moreover, DNMT1 methylation at K142 occurs in oppos-
ition to its phosphorylation. While phosphorylation of
DNMT1 had been shown to affect its methyltransferase activ-
ity [46] and its interaction with PCNA and UHRF1 [47], it
also plays a role in DNMT1 stability [33]. When v-akt murine
thymoma viral oncogene homolog 1 phosphorylates DNMT1
at S143, Set7 becomes unable to methylate DNMT1 at K142
and DNMT1 is stabilized. Much like ubiquitination, DNMT1
phosphorylation changes during the cell cycle: another
example of the relationship between DNMT1 stability and ap-
propriate timing of DNA methylation.
Regulation of DNMT1 Protein Stability by
Associated Proteins
DNMT1 interacts with a multitude of proteins that have
varying functions within the cell [48]. These proteins various-
ly affect DNMT1 stability, activity, and localization. As an
example, we recently identified an interaction between
DNMT1 protein and the wingless-type mouse mammary
tumor virus integration site family (Wnt) pathway effector,
b-catenin. DNMT1 levels increase upon stimulation with
Wnt3a in a b-catenin-dependent manner; moreover, the inter-
action between b-catenin and DNMT1 is mutually stabilizing
(J. Song, Z. Wang and R. Ewing, unpublished data). Given
the crucial role of Wnt signaling in development, these find-
ings suggest a mechanism by which developmental cues can
have an impact on the epigenetic landscape of a developing
organism.
Therapeutic Implications
Several USA Food and Drug Administration approved epi-
genetic drugs have been shown to target DNMT1 protein
stability. DNMT1 inhibitors (DNMTi), azacitidine and deci-
tabine, are used to treat myelodysplastic syndromes.
Canonically, they act via targeting DNMT1 [49], covalently
binding with DNA methyltransferases to inactivate them
[50–52]. However, recent research demonstrates that
DNMTi also induce the proteosomal degradation of
DNMT1 [53–55]. Interestingly, HDAC inhibitors (HDACi),
another kind of epigenetic drug, also cause proteasome-
mediated DNMT1 degradation [7,26]. HDACi, such as vori-
nostat, are currently on the market for treating cutaneous
T-cell lymphoma [56]. However, neither HDACi nor
DNMTi as single agent has an effect on solid tumors.
Several ongoing clinical trials indicate that at least a subset
of lung cancer patients is responsive to combination treat-
ment of HDACi and DNMTi [57].
The HDAC1-HAUSP axis of DNMT1 regulation provides
rationale for novel combinatorial therapy options. Knockout of
HAUSP in colon cancer cells potentiates HDACi-induced
DNMT1 degradation and thus enhances the tumor inhibitory
effect of HDACi in a xenograft tumor model. [26]. These
observations suggest that combination of HDACi with a
HAUSP inhibitor (HAUSPi) may be an effective approach to
treat solid tumors. In fact, several distinct HAUSPi have been
developed. Some, such as HBX 19,818 [58,59] and P5091
[60,61] were derived from high-throughput compound
screens. Another group rationally derived a peptide based on
the interaction between HAUSP and a viral protein that inhi-
bits its deubiquitinase activity [62]. Moreover, a compound
isolated from sponges also has anti-HAUSP activity [63].
Many of these demonstrate cytotoxicity in vitro and in animal
models of disease, particularly through potentiating
p53-mediated apoptosis. As predicted by the interaction
between HDAC1 and HAUSP, two different HAUSPis dem-
onstrate synergistic effects with HDACi in cell culture [61,
and P. Zhang and Z. Wang, unpublished data].
Perspectives and Future Directions
As increasing emphasis is placed on epigenetic mechanisms
of gene expression, understanding DNMT1 stability and
regulation becomes paramount. Like many other proteins,
post-translational modifications of DNMT1 play a crucial
role in how and when it is activated. When this protein
becomes dysregulated, aberrant methylation patterns and
subsequent tumor initiation can occur. Anti-cancer therapies
increasingly emphasize the release of tumor suppressor
genes from epigenetic mechanisms of repression [64,65].
One important way to effect this goal is to choose com-
pounds that can affect DNMT1 stability.
An important outstanding question in the field of DNMT1
and cancer development is the mechanism by which specific
loci become silenced, especially in the context of global
demethylation. Compounds that target specific loci for
demethylation rather than causing global hypomethylation
have an advantage from a therapeutic perspective, preventing
chromosomal instability while restoring tumor suppressor
expression; one such compound is the DNMT1 inhibitor
RG108 [66]. Long non-coding RNAs (lincRNAs) are pro-
posed as a way for gene silencing machinery to target-
specific gene loci [9,67,68]. It has been shown that the
lincRNA, KCNQ1 opposite strand/antisense transcript 1,
interacts with DNMT1 and mediates imprinting at imprinted
loci. A recent study demonstrated that a nuclear RNA tran-
scribed from the CCAAT/enhancer binding protein alpha
(CEBPA) locus interacts with DNMT1, blocks it from that
locus and thus inhibits methylation around CEBPA’s pro-
moter [69]. It is possible that other DNMT1-associated
RNAs target DNMT1 around other gene loci or specific
chromatin regions. In addition, the DNMT1 binding partner
UHRF1 contains domains that bind specific H3 tail modifi-
cations and therefore can target DNMT1 to specific loci via
the histone code [70]. Protein–protein interactions are also
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implicated, as the DNMT1-binding partner nibrin helps
DNMT1 localize and repress survivin during DNA damage
[71]. Other evidence suggests that the N-terminal domains of
DNMT1, while not necessary for catalytic methyltransferase
activity, are still important to target the protein to correct
genomic locations [72]. Extending these models to tumor
suppressor loci will be useful in expanding the role of
DNMT1 in tumorigenesis and may belie alternate mechan-
isms for treatment.
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